FDA clears portable hematology analyzer

Print Friendly, PDF & Email


HemoScreen
Photo courtesy of
PixCell Medical
The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for PixCell Medical’s HemoScreen™. This portable hematology analyzer is used to perform a complete blood count at the point of care. HemoScreen requires a single drop of blood and uses disposable cartridges that provide automatic sample preparation.... [Read Article]
Print Friendly, PDF & Email

CPI-0610 receives fast track designation for MF

Print Friendly, PDF & Email


Micrograph showing myelofibrosis
The U.S. Food and Drug Administration (FDA) has granted fast track designation to CPI-0610 for the treatment of myelofibrosis (MF). CPI-0610 is a BET inhibitor being developed by Constellation Pharmaceuticals, Inc. The company said results from preclinical studies and translational insights from the first-in-human study of CPI-0610 led to the prioritization... [Read Article]
Print Friendly, PDF & Email

Adoptive T-cell therapy treats PML

Print Friendly, PDF & Email


JC virus protein (brown)
in a brain biopsy (glial
cells demonstrating PML)
Image by Marvin 101
Adoptive T-cell therapy has proven effective for treating progressive multifocal leukoencephalopathy (PML), according to research published in The New England Journal of Medicine. Researchers observed substantial improvements in three PML patients infused with donor T cells targeting the... [Read Article]
Print Friendly, PDF & Email

The challenges of diagnosing CMML

Print Friendly, PDF & Email


Micrograph showing CMML
Image by Simon Caulton
Diagnosing chronic myelomonocytic leukemia (CMML) remains a challenge in 2018, according to a presentation at Leukemia and Lymphoma: Europe and the USA, Linking Knowledge and Practice. Even with updated World Health Organization (WHO) criteria, karyotyping, and genetic analyses, it can be difficult to distinguish CMML from other conditions,... [Read Article]
Print Friendly, PDF & Email

Genomic findings may predict outcomes in MPN patients

Print Friendly, PDF & Email


Essential thrombocythemia
New research suggests genomic characteristics of patients with myeloproliferative neoplasms (MPNs) can predict clinical outcomes. Investigators defined eight genomic subgroups of MPNs, each with distinct clinical features, including event-free survival, risk of leukemic transformation, and blood counts. Jacob Grinfeld, MD, of the University of Cambridge in the U.K., and his colleagues described... [Read Article]
Print Friendly, PDF & Email

AMP publishes report on DNA variants in CMNs

Print Friendly, PDF & Email


Polycythemia vera
Image courtesy of AFIP
A new report addresses the clinical relevance of DNA variants in chronic myeloid neoplasms (CMNs). The report is intended to aid clinical laboratory professionals with the management of most CMNs and the development of high-throughput pan-myeloid sequencing testing panels. The authors list 34 genes they consider “critical” for sequencing... [Read Article]
Print Friendly, PDF & Email

Familial risk of myeloid malignancies

Print Friendly, PDF & Email


Three generations of
women in a family
A large study has revealed “the strongest evidence yet” supporting genetic susceptibility to myeloid malignancies, according to a researcher. The study showed that first-degree relatives of patients with myeloid malignancies had double the risk of developing a myeloid malignancy themselves, when compared to the general population. The researchers... [Read Article]
Print Friendly, PDF & Email

JAK inhibition linked to B-cell lymphoma

Print Friendly, PDF & Email


Micrograph showing myelofibrosis
New research indicates that JAK inhibitors may increase the risk of lymphoma in patients with myelofibrosis (MF). The patients studied had a 15- to 25-fold higher risk of developing B-cell lymphoma if they received treatment with JAK inhibitors. The researchers speculate that screening MF patients for a pre-existing B-cell clone before starting... [Read Article]
Print Friendly, PDF & Email

Ropeg outperforms HU in PV patients of all ages

Print Friendly, PDF & Email


The 23rd Congress of the
European Hematology Association
Follow-up data suggest that ropeginterferon alfa-2b (ropeg) provides an advantage over hydroxyurea (HU) for patients with polycythemia vera (PV), regardless of their age. Two-year results from an extension study have shown that, compared to HU, ropeg produces higher rates of complete hematologic response (CHR) and molecular response... [Read Article]
Print Friendly, PDF & Email

Umbralisib can revitalize ruxolitinib in MF

Print Friendly, PDF & Email


Poster session at the 23rd Congress of the European Hematology Association
The PI3K delta inhibitor umbralisib can “augment or resurrect” responses to ruxolitinib in patients with myelofibrosis (MF), according to a speaker at the 23rd Congress of the European Hematology Association (EHA). Results of a phase 1 study showed that adding umbralisib to treatment with... [Read Article]
Print Friendly, PDF & Email

PU-H71 receives orphan drug designation for myelofibrosis

Print Friendly, PDF & Email


Micrograph showing myelofibrosis
The US Food and Drug Administration (FDA) has granted orphan drug designation to PU-H71 to treat patients with myelofibrosis. The drug specifically targets the epichaperome, a network of high-molecular- weight complexes found in multiple diseases, including cancer and neurologic disorders. These complexes enhance cellular survival, irrespective of tissue of origin or... [Read Article]
Print Friendly, PDF & Email